omeprazole has been researched along with Malignant Melanoma in 3 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This phase I/II study in patients with advanced melanoma evaluated the potential effect of sorafenib on the pharmacokinetics of midazolam, omeprazole, and dextromethorphan, specific substrates of CYP3A4, CYP2C19, and CYP2D6, respectively." | 9.15 | Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ( Flaherty, KT; Frye, RF; Lathia, C; O'Dwyer, PJ; Redlinger, M; Rosen, M; Schuchter, L, 2011) |
| " This phase I/II study in patients with advanced melanoma evaluated the potential effect of sorafenib on the pharmacokinetics of midazolam, omeprazole, and dextromethorphan, specific substrates of CYP3A4, CYP2C19, and CYP2D6, respectively." | 5.15 | Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ( Flaherty, KT; Frye, RF; Lathia, C; O'Dwyer, PJ; Redlinger, M; Rosen, M; Schuchter, L, 2011) |
| "We pretreated cell lines derived from human melanomas, adenocarcinomas, and lymphomas with the PPIs omeprazole, esomeprazole, or pantoprazole and tested their response to cytotoxic drugs in cell death assays." | 3.72 | Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. ( Arancia, G; Belardelli, F; De Milito, A; Fais, S; Federici, C; Iessi, E; Logozzi, M; Lozupone, F; Luciani, F; Lugini, L; Marra, M; Molinari, A; Montinaro, A; Parmiani, G; Rivoltini, L; Spada, M, 2004) |
| "Omeprazole treatment increased the proportion of EndoH sensitive tyrosinase, indicating that tyrosinase maturation was impaired." | 1.42 | Omeprazole, a gastric proton pump inhibitor, inhibits melanogenesis by blocking ATP7A trafficking. ( Ichihashi, M; Karaman-Jurukovska, N; Matsui, MS; Muizzuddin, N; Niki, Y; Petris, MJ; Yarosh, DB, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsui, MS | 1 |
| Petris, MJ | 1 |
| Niki, Y | 1 |
| Karaman-Jurukovska, N | 1 |
| Muizzuddin, N | 1 |
| Ichihashi, M | 1 |
| Yarosh, DB | 1 |
| Flaherty, KT | 1 |
| Lathia, C | 1 |
| Frye, RF | 1 |
| Schuchter, L | 1 |
| Redlinger, M | 1 |
| Rosen, M | 1 |
| O'Dwyer, PJ | 1 |
| Luciani, F | 1 |
| Spada, M | 1 |
| De Milito, A | 1 |
| Molinari, A | 1 |
| Rivoltini, L | 1 |
| Montinaro, A | 1 |
| Marra, M | 1 |
| Lugini, L | 1 |
| Logozzi, M | 1 |
| Lozupone, F | 1 |
| Federici, C | 1 |
| Iessi, E | 1 |
| Parmiani, G | 1 |
| Arancia, G | 1 |
| Belardelli, F | 1 |
| Fais, S | 1 |
1 trial available for omeprazole and Malignant Melanoma
| Article | Year |
|---|---|
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Topics: Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Cytochrome P-450 Enzyme System; Dextrome | 2011 |
2 other studies available for omeprazole and Malignant Melanoma
| Article | Year |
|---|---|
Omeprazole, a gastric proton pump inhibitor, inhibits melanogenesis by blocking ATP7A trafficking.
Topics: Adenosine Triphosphatases; Animals; Cation Transport Proteins; Cell Line, Tumor; Cells, Cultured; Co | 2015 |
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Animals; Antineoplastic Agents; Benzimidazo | 2004 |